Study

HSP-1/HSPA8 directs selective translation towards longevity or immunity

Greer E, Sarkar G, McNinch C, Khan A, Mitchell W, Urs AN, Nakamura K, Zaher H, Gladyshev V

MECHANISTIC PREPRINT USING C. ELEGANS AND HUMAN CELLS 2026

A mechanistic preprint connects HSP-1/HSPA8, translation control, lysosomal function and the trade-off between longevity and immunity.

DesignMECHANISTIC PREPRINT USING C. ELEGANS AND HUMAN CELLS
TierTier 3, Ingredient RCT (matching dose)
Year2026
JournalResearch Square preprint
Nnot stated in the abstract
PublishedSep 23, 2026
Added to NO1GEVITYSep 27, 2026

Greer and colleagues describe HSP-1 in C. elegans and its human orthologue HSPA8 as a translation-control node that can shift cells toward longevity or immunity. HSP-1 depletion accelerated aging, removed the lifespan benefit associated with reduced translation, impaired lysosomal acidification and autophagy, and activated p38-MAPK immune signalling. HSPA8 depletion in human cells produced related changes in p38 signalling and lysosomal biology. The proposed model is that translation reduction is not a single beneficial switch. It changes the allocation of cellular resources, and HSP-1 helps determine whether the result supports maintenance or immune activation. This could help explain why broad translation or mTOR interventions have context-dependent effects. The evidence is mechanistic and preclinical. The abstract does not provide a human intervention, a validated aging biomarker endpoint or a dose that can be used clinically. HSPA8 is a core chaperone, so direct inhibition would carry substantial biological risk. The paper is useful for mechanism mapping but does not support a supplement, drug or evidence-grade change.

HSP-1/HSPA8 directs selective translation towards longevity or immunity.
Critic notes

Preprint and mechanistic work. C. elegans and cell assays do not establish human healthspan effects or a safe intervention target.

Read the source